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Summary 
Osteoporosis is a very common medical condition while os-
teoporosis related fractures could lead to significant disability and 
poor quality of life. There are several medications which are clas-
sified as the causes for osteoporosis, such as corticosteroids or an-
tiepileptic drugs.
1,2 Recently, an association between proton 
pump inhibitors (PPIs) and hip fracture was suggested.
3,4 This is 
primarily based on evidence from epidemiologic analyses show-
ing a significant association between chronic PPI use and the risk 
of hip fracture. 
The present study was conducted to determine whether 
chronic PPI use is associated with an increased risk of osteopo-
rosis based on bone mineral densitometry in cross sectional study 
and whether continued use of a PPI leads to an increased rate of 
bone mineral density (BMD) decline in longitudinal study 
setting.
5
Two separate analyses were performed. In the cross-sectional 
study, authors compared subjects with established osteoporosis, 
as determined by BMD testing, to controls with normal BMD. 
In the longitudinal study, they analyzed the change in BMD on 
serial assessments between PPI users and non-PPI users. The 
Manitoba Centre for Health Policy maintains the Population 
Health Research Data Repository. It includes a comprehensive 
collection of population-based health utilization data sets and the 
Drug Programs Information Network data set, giving re-
searchers the ability to construct a longitudinal medical history 
for any person registered with the Manitoba Health Services 
Insurance Plan.
6 Osteoporosis was defined by dual-energy X-ray 
absorptiometry, or DXA scanning in the Provincial Bone Miner-
al Density Database. 
In the cross-sectional study, 2,193 subjects had evidence of 
osteoporosis at the hip and were matched to 5,527 controls with 
normal hip measurements. A total of 3,596 subjects had BMD 
measurements consistent with osteoporosis at the lumbar spine 
and were in turn matched to 10,257 normal controls. In uni-
variate analyses, PPI use was associated with a lower risk of os-
teoporosis at the lumbar spine for all levels of PPI use, however, 
after adjusting for potential confounders through conditional 
multivariable logistic regression, no association was observed be-
tween PPI use and osteoporosis at either the hip or the lumbar 
spine.
In the longitudinal study, they identified 2,549 subjects who 
underwent 2 separate BMD assessments with mean follow-up 
period of 2.31 ± 0.5 years. Hye-Kyung Jung
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The use of standard dose of PPIs over the time between 
BMD assessments did not have a statistically significant effect on 
the rate of BMD decline, either at the lumbar spine (change in 
BMD, 0.03% ± 0.22%; p > 0.2) or the total hip (change in 
BMD, -0.17% ± 0.18%; p > 0.2). The use of bisphosphonates, 
systemic estrogens and estrogen receptor modulators was asso-
ciated with a significant annual increase in BMD at both sites 
(adjusted p < 0.0001), whereas the use of corticosteroids was as-
sociated with a significantly greater decline in BMD at both the 
lumbar spine and hip in the adjusted analyses.
Comment
PPIs are widely used in clinical practice and physicians gen-
erally consider this drug as one of the safest to prescribe. The pre-
vious nested case-control study in the General Practice Research 
Database showed a significant association between chronic PPIs 
use and hip fracture in a dose dependent manner.
3 Acid sup-
pressive therapy might impair calcium absorption and therefore 
increase the risk of silent osteoporosis. PPI use in juvenile rats 
has been shown to decrease both bone density and peak bone 
mineral mass.
7 However, there is little direct evidence that links 
the use of PPIs to the development of osteoporosis. Gastrectomy 
has been associated with decrease in BMD.
8 Gastrectomy in-
duces hypergastrinemia which may induce parathyroid hyper-
plasia and promote bone calcium loss.
9 However, vagotomy with-
out gastrectomy does not induce bone density loss and altogether 
these findings support the limited role of acid suppression in the 
development of osteoporosis.
10
The present study postulates that chronic PPI use not to be 
associated with an increased risk of osteoporosis as determined by 
BMD testing, despite evidences linking their use to an increased 
risk of fractures. However, the absolute risk of hip fracture sec-
ondary to PPI therapy was very small. Notably, the crude in-
cidence rate of hip fracture was nearly 2 per 1,000 person among 
non-PPI users, and this only increased to 4 per 1,000 person with 
more than 1 year of PPI use.
3,11  
PPIs are safe medicines, however, PPIs are often chronically 
used in situation in which patients are at high risk for declined 
bone density, such as chronic corticosteroid user, chronic debili-
tating conditions or old ages. At this time, there is no definitive 
evidence to discontinue the long-term PPI use, however, we need 
further prospective studies on the effect of PPI use on the bone 
mineral metabolism and bone health.
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